Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

Despite quarterly revenue totals that were nearly cut in half compared to the same period last year, Moderna still expects to ...

A Moderna COVID-19 vaccine (brand name: Spikevax) photographed at Borinquen Health Care Center on May 29 in Miami. (Photo illustration by Joe Raedle/Getty Images) The Food and Drug Administration ...

Moderna swung to a loss and logged lower sales in the third quarter as it works to expand its offerings amid weakening demand ...

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

A stunning new study offers early evidence that COVID-19 vaccines might have a secret superpower: a precisely timed mRNA shot could help many cancer patients live longer.

LOS ANGELES -- The COVID-19 vaccines made by Pfizer and Moderna both require two doses to be administered, several weeks apart, for them to be fully effective. But there has been some scientific ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in LP.8.1-neutralizing antibodies across age groups Clinical findings reinforce preclinical data ...